Kidney Cancer Journal

A Phase II Study of the Efficacy and Safety of Axitinib (Axi) Given on an Individualized Schedule for metastatic renal cell carcinoma (mRCC) after treatment with PD-1 / PD-L1 Inhibitors NCT02579811

Posted by Kidney Cancer Journal | Mar 2018

A Phase II Study of the Efficacy and Safety of Axitinib (Axi) Given on an Individualized Schedule...

A phase I, open label, dose escalation and cohort expansion study to evaluate the safety and immune response to autologous dendritic cells transduced with AdGMCA9 in patients with metastatic renal cell carcinoma

Posted by Kidney Cancer Journal | Mar 2018

A phase I, open label, dose escalation and cohort expansion study to evaluate the safety and...

A Phase 3 Trial to Compare Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab vs Sunitinib Alone in First-line Treatment of Patients With Metastatic Renal Cell Carcinoma S2

Posted by Kidney Cancer Journal | Mar 2018

A Phase 3 Trial to Compare Efficacy and Safety of Lenvatinib in Combination With Everolimus or...

A Phase 2 Trial of Lenvatinib 18 mg vs 14 mg Once Daily (QD) in Combination With Everolimus (5 mg QD) in Renal Cell Carcinoma S1

Posted by Kidney Cancer Journal | Mar 2018

A Phase 2 Trial of Lenvatinib 18 mg vs 14 mg Once Daily (QD) in Combination With Everolimus (5 mg...

A Phase 1b/2 Trial of Lenvatinib+Pembrolizumab in Patients With Renal Cell Carcinoma S1

Posted by Kidney Cancer Journal | Mar 2018

A Phase 1b/2 Trial of Lenvatinib+Pembrolizumab in Patients With Renal Cell Carcinoma S1 Abstract...

Join the GRU Community

- Why Join? -

CARDEN JENNINGS PUBLISHING CO., LTD.

Your GRU

– Account Dashboard
– Your Courses

Recent Updates

PDF Embedder Test Jan 2022
Genetic Testing and Prostate Cancer – Welcome Jan 2022
Current Status of PSMA Diagnostics Aug 2021
Genetic Testing and Prostate Cancer Aug 2021
What’s New in Active Surveillance for Prostate Cancer in 2021 Aug 2021

Kidney Cancer Journal

A Phase II Study of the Efficacy and Safety of Axitinib (Axi) Given on an Individualized Schedule for metastatic renal cell carcinoma (mRCC) after treatment with PD-1 / PD-L1 Inhibitors NCT02579811

A phase I, open label, dose escalation and cohort expansion study to evaluate the safety and immune response to autologous dendritic cells transduced with AdGMCA9 in patients with metastatic renal cell carcinoma

A Phase 3 Trial to Compare Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab vs Sunitinib Alone in First-line Treatment of Patients With Metastatic Renal Cell Carcinoma S2

A Phase 2 Trial of Lenvatinib 18 mg vs 14 mg Once Daily (QD) in Combination With Everolimus (5 mg QD) in Renal Cell Carcinoma S1

A Phase 1b/2 Trial of Lenvatinib+Pembrolizumab in Patients With Renal Cell Carcinoma S1

Join the GRU Community

You have Successfully Subscribed!

CARDEN JENNINGS PUBLISHING CO., LTD.

INFO

Your GRU

– Account Dashboard
– Your Courses

Recent Updates

Exercise & Wellness

Kidney Cancer Journal

A Phase II Study of the Efficacy and Safety of Axitinib (Axi) Given on an Individualized Schedule for metastatic renal cell carcinoma (mRCC) after treatment with PD-1 / PD-L1 Inhibitors NCT02579811

A phase I, open label, dose escalation and cohort expansion study to evaluate the safety and immune response to autologous dendritic cells transduced with AdGMCA9 in patients with metastatic renal cell carcinoma

A Phase 3 Trial to Compare Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab vs Sunitinib Alone in First-line Treatment of Patients With Metastatic Renal Cell Carcinoma S2

A Phase 2 Trial of Lenvatinib 18 mg vs 14 mg Once Daily (QD) in Combination With Everolimus (5 mg QD) in Renal Cell Carcinoma S1

A Phase 1b/2 Trial of Lenvatinib+Pembrolizumab in Patients With Renal Cell Carcinoma S1

Join the GRU Community

You have Successfully Subscribed!

CARDEN JENNINGS PUBLISHING CO., LTD.

INFO

Your GRU

– Account Dashboard – Your Courses

Recent Updates

Exercise & Wellness

– Account Dashboard
– Your Courses